Cabaletta Bio (CABA) Receives a Rating Update from a Top Analyst


In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Cabaletta Bio (CABA), with a price target of $21.00. The company’s shares closed last Monday at $10.72.

According to TipRanks.com, Livshits is a top 100 analyst with an average return of 75.0% and a 71.2% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Crispr Therapeutics AG, and Intellia Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cabaletta Bio with a $21.50 average price target, representing an 89.9% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $22.00 price target.

See today’s analyst top recommended stocks >>

Based on Cabaletta Bio’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $9.31 million. In comparison, last year the company had a GAAP net loss of $5.4 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in 2017 and is headquartered in Philadelphia, PA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts